The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

  • See Evidence submitted by expert panel for details.

Variant: NM_000277.2(PAH):c.1163T>C (p.Val388Ala)

CA267628

120260 (ClinVar)

Gene: PAH
Condition: phenylketonuria
Inheritance Mode: Autosomal recessive inheritance
UUID: 4a58fdc9-98c8-41a1-90fc-e0e94d381492

HGVS expressions

NM_000277.2:c.1163T>C
NM_000277.2(PAH):c.1163T>C (p.Val388Ala)
NC_000012.12:g.102843682A>G
CM000674.2:g.102843682A>G
NC_000012.11:g.103237460A>G
CM000674.1:g.103237460A>G
NC_000012.10:g.101761590A>G
NG_008690.1:g.78921T>C
NG_008690.2:g.119729T>C
NM_000277.1:c.1163T>C
NM_001354304.1:c.1163T>C
NM_000277.3:c.1163T>C
ENST00000307000.7:c.1148T>C
ENST00000549247.6:n.922T>C
ENST00000551114.2:n.825T>C
ENST00000553106.5:c.1163T>C
ENST00000635477.1:n.267T>C
ENST00000635528.1:n.678T>C

Likely Pathogenic

Met criteria codes 4
PP3 PP4 PM5 PM2
Not Met criteria codes 1
PM3

Evidence Links 1

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
Phenylketonuria VCEP
The c.1163T>C (p.Val388Ala) variant in PAH has been previously reported Likely Pathogenic by one clinical laboratory in ClinVar (see variant ID 120260); the collection method is stated as “literature only” and no further information is provided. With respect to the published literature, it has been previously reported in a French proband classified as having mild PKU (defined by the authors as plasma phenylalanine levels between 600-1200uL/L) (PMID: 26666653); formal testing to exclude BH4 deficiency was not noted (PP4). The proband was said to be heterozygous for the variant and also harbor the known pathogenic (per ClinGen PAH working group classification, see ClinVar ID 92731) c.1208C>T (Ala403Val); however, the manuscript did not specify whether the phase of the variants was confirmed via parental testing. Thus, at this point, PM3 cannot be applied with full confidence. The variant results in the substitution of a moderately conserved Valine residue with Alanine, a physiochemically similar amino acid. However, the amino acid substitution is predicted damaging by multiple lines of computational evidence e.g., Predicted deleterious in SIFT, Polyphen2, Mutation Taster. REVEL= 0.919) (PP3). It is absent from control databases including ethnically matched individuals, including gnomAD/ExAC, 1000 Genomes, and ESP (PM2). Other missense changes at this Valine residue (Val388) have been previously reported Pathogenic or Likely Pathogenic in ClinVar, e.g., p.Val388Met (Pathogenic per internal PAH ClinGen Working Group classification, ClinVar ID 619), as well as p.Val388Leu (PM5). The c.181A>G (p.Asn61Asp) variant in PAH has been reported in 1 individual with mild PKU (BH4 deficiency excluded). (PP4_Moderate; PMID: 12501224). This variant is absent in population databases (PM2). This variant was detected with p.R261Q (Pathogenic/likely pathogenic in ClinVar) (PM3; PMID: 12501224). Computational evidence is conflicting. In summary, this variant meets criteria to be classified as likely pathogenic for PAH. PAH-specific ACMG/AMP criteria applied: PP4, PM2, PM5, PP3.
Met criteria codes
PP3
The variant results in the substitution of a moderately conserved Valine residue with Alanine, a physiochemically similar amino acid. However, the amino acid substitution is predicted damaging by multiple lines of computational evidence e.g., Predicted deleterious in SIFT, Polyphen2, Mutation Taster. REVEL= 0.919) (PP3).
PP4
The c.1163T>C (p.Val388Ala) variant in PAH has been previously reported Likely Pathogenic by one clinical laboratory in ClinVar (see variant ID 120260); the collection method is stated as “literature only” and no further information is provided. With respect to the published literature, it has been previously reported in a French proband classified as having mild PKU (defined by the authors as plasma phenylalanine levels between 600-1200uL/L) (PMID: 26666653); formal testing to exclude BH4 deficiency was not noted (PP4). The proband was said to be heterozygous for the variant and also harbor the known pathogenic (per ClinGen PAH working group classification, see ClinVar ID 92731) c.1208C>T (Ala403Val); however, the manuscript did not specify whether the phase of the variants was confirmed via parental testing. Thus, at this point, PM3 cannot be applied with full confidence.

PM5
Other missense changes at this Valine residue (Val388) have been previously reported Pathogenic or Likely Pathogenic in ClinVar, e.g., p.Val388Met (Pathogenic per internal PAH ClinGen Working Group classification, ClinVar ID 619), as well as p.Val388Leu (PM5).
PM2
It is absent from control databases including ethnically matched individuals, including gnomAD/ExAC, 1000 Genomes, and ESP (PM2).
Not Met criteria codes
PM3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
Approved on: 2019-05-05
Published on: 2019-07-19
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.